Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental vaccine aims to train immune system to fight HPV cancers

NCT ID NCT06319963

Summary

This early-stage trial is testing a new therapeutic vaccine called Lenti-HPV-07 in people with HPV-related throat or cervical cancer. The main goals are to see if the vaccine is safe and if it can trigger the body's immune system to fight the cancer. The study will enroll 72 participants, who will be followed for up to one year after treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Cancer Specialists (from Sarah Canon research Institute)

    RECRUITING

    Orlando, Florida, 32827, United States

    Contact

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

  • Oklahoma Cancer Specialists and Research Institute, LLC

    RECRUITING

    Tulsa, Oklahoma, 74146, United States

    Contact

  • Tampa General Hospital

    RECRUITING

    Tampa, Florida, 33606, United States

    Contact

Conditions

Explore the condition pages connected to this study.